Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

NCT01958918 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

712

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab
DRUG: Aflibercept

Sponsor

Novartis Pharmaceuticals